SAN DIEGO --(BUSINESS WIRE)--Jun. 2, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.
Revenues of $17.8 million were driven by RT-PCR COVID-19 testing Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system Received approximately 390,000 COVID-19 samples since June 2020
SAN DIEGO --(BUSINESS WIRE)--May 5, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ended March 31, 2021 after the market closes on Wednesday, May 12, 2021 .
Foundation offers COVID-19 testing and support to more than 2.1 million students as part of campus health services SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has partnered with the Foundation
Molecular assay provides highly sensitive, quantitative method to identify cancer involving the central nervous system, inform treatment decisions, and monitor therapy response SAN DIEGO --(BUSINESS WIRE)--Apr. 21, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020 , it has now received more than 350,000 samples for testing.
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University W ebinar begins tomorrow, April 8 , at 12:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2021-- Biocept, Inc.
SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees.
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
Q4 features revenues of $18.5 million ; 2020 revenues reach $27.5 million driven by COVID-19 testing Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system Conference call begins at 4:30 p.m.